DekaBank Deutsche Girozentrale reduced its position in MetLife, Inc. (NYSE:MET) by 10.4% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 217,487 shares of the financial services provider’s stock after selling 25,379 shares during the period. DekaBank Deutsche Girozentrale’s holdings in MetLife were worth $12,145,000 at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of the company. Signature Estate & Investment Advisors LLC bought a new position in MetLife during the first quarter worth approximately $107,000. First Personal Financial Services raised its position in MetLife by 11.5% in the first quarter. First Personal Financial Services now owns 2,588 shares of the financial services provider’s stock worth $137,000 after buying an additional 266 shares during the last quarter. Westside Investment Management Inc. raised its position in MetLife by 583.8% in the first quarter. Westside Investment Management Inc. now owns 2,694 shares of the financial services provider’s stock worth $140,000 after buying an additional 2,300 shares during the last quarter. Parallel Advisors LLC raised its position in MetLife by 50.7% in the first quarter. Parallel Advisors LLC now owns 2,748 shares of the financial services provider’s stock worth $143,000 after buying an additional 924 shares during the last quarter. Finally, First Mercantile Trust Co. bought a new position in MetLife during the first quarter worth approximately $149,000. 74.23% of the stock is owned by hedge funds and other institutional investors.

Shares of MetLife, Inc. (MET) opened at 47.06 on Thursday. MetLife, Inc. has a 52-week low of $37.17 and a 52-week high of $52.07. The stock has a market cap of $50.02 billion, a P/E ratio of 553.65 and a beta of 1.46. The firm’s 50-day moving average price is $48.46 and its 200-day moving average price is $47.25.

MetLife (NYSE:MET) last posted its quarterly earnings results on Wednesday, August 2nd. The financial services provider reported $1.30 earnings per share for the quarter, topping analysts’ consensus estimates of $1.28 by $0.02. The firm had revenue of $17.39 billion for the quarter, compared to analyst estimates of $17.11 billion. MetLife had a net margin of 0.30% and a return on equity of 8.51%. MetLife’s quarterly revenue was up 2.5% on a year-over-year basis. During the same period in the previous year, the business posted $0.83 earnings per share. Equities analysts predict that MetLife, Inc. will post $4.78 EPS for the current year.

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, September 13th. Investors of record on Monday, August 7th will be given a dividend of $0.40 per share. The ex-dividend date of this dividend is Thursday, August 3rd. This represents a $1.60 dividend on an annualized basis and a yield of 3.40%. MetLife’s payout ratio is presently 1,777.98%.

COPYRIGHT VIOLATION WARNING: “DekaBank Deutsche Girozentrale Has $12.15 Million Stake in MetLife, Inc. (MET)” was first reported by Watch List News and is the property of of Watch List News. If you are accessing this news story on another domain, it was illegally stolen and reposted in violation of US & international copyright and trademark laws. The original version of this news story can be accessed at https://www.watchlistnews.com/dekabank-deutsche-girozentrale-has-12-15-million-stake-in-metlife-inc-met/1533078.html.

Several research firms recently issued reports on MET. Langen Mcalenn reissued a “buy” rating on shares of MetLife in a research note on Wednesday, August 16th. Wells Fargo & Co reissued a “buy” rating on shares of MetLife in a research note on Monday, August 7th. BidaskClub raised MetLife from a “sell” rating to a “hold” rating in a research note on Wednesday, August 9th. Keefe, Bruyette & Woods reissued a “buy” rating and set a $59.00 price objective on shares of MetLife in a research note on Thursday, August 3rd. Finally, Zacks Investment Research lowered MetLife from a “hold” rating to a “sell” rating in a research note on Wednesday, August 9th. Two analysts have rated the stock with a sell rating, six have issued a hold rating and ten have assigned a buy rating to the company’s stock. The company presently has an average rating of “Hold” and an average price target of $58.95.

MetLife Company Profile

MetLife, Inc is a provider of life insurance, annuities, employee benefits and asset management. The Company’s segments include U.S.; Asia; Latin America; Europe, the Middle East and Africa (EMEA); MetLife Holdings, and Corporate & Other. Its U.S. segment is organized into Group Benefits, Retirement and Income Solutions and Property & Casualty businesses.

Institutional Ownership by Quarter for MetLife (NYSE:MET)

Receive News & Ratings for MetLife Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MetLife Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.